Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Everolimus + Lenvatinib & Renal cell carcinoma (RCC), Everolimus + Lenvatinib received FDA approval in May 2016 for patients with advanced Renal cell carcinoma (RCC) following one prior antiangiogenic therapy (e.g., prior VEGFR‑TKI). The approval was based on a randomized phase II study (Study 205) showing significantly improved progression‑free survival and response rate versus everolimus monotherapy in previously treated metastatic Renal cell carcinoma (RCC) (1, 2)